Correction: Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease (Neurology (2012) 78 (1576-1582) DOI: 10.1212/WNL.0b013e3182563bbe);Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

Neurology

Volumn 78, Issue 20, 2012, Pages 1576-1582

  Knopman, D S ^a,b   Jack, C R ^a,b   Wiste, H J ^a   Weigand, S D ^a   Vemuri, P ^a   Lowe, V ^a   Kantarci, K ^a   Gunter, J L ^a   Senjem, M L ^a   Ivnik, R J ^b,c   Roberts, R O ^b   Boeve, B F ^a,b   Petersen, R C ^a,b  

^a Department of Neurology ^*  (United States)

^b MAYO CLINIC   (United States)

^c Division of Epidemiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; 2 (4' (METHYLAMINO)PHENYL) 6 HYDROXYBENZOTHIAZOLE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; BRAIN; CHI SQUARE DISTRIBUTION; COGNITIVE DEFECT; METABOLISM; NATIONAL HEALTH ORGANIZATION; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; UNITED STATES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NATIONAL INSTITUTE ON AGING (U.S.); NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; THIAZOLES; UNITED STATES;

EID: 84863185648     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004318     Document Type: Erratum

References (40)

1. Sperling RA, Aisen P, Beckett L, et al. Towards defining the preclinical stage of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement 2011; 7:280-292.
2. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging- Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol Epub 2011 Sep 12.
3. Roe CM, Fagan AM, Williams MM, et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 2011;76:501-510.
4. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-192.
5. Roberts RO, Geda YE, Knopman D, et al. The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69.
6. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men than in women: The Mayo Clinic Study of Aging. Neurology 2010;75:889-897.
7. Knopman DS, Petersen RC, Rocca WA, Larson EB, Ganguli M. Passive case-finding for Alzheimer's disease and dementia in two U.S. communities. Alzheimers Dement 2011;7:53-60.
8. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. Neurology 2012;78:342-351.
9. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
11. Ivnik RJ, Malec JF, Smith GE. WAIS-R, WMS-R and AVLT norms for ages 56 through 97. Clin Neuropsychol 1992;6(suppl):83-104.
12. Jack CR Jr, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010; 6:212-220.
13. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-355.
14. Jack CR Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: Normative volumetric measurements from MR images in young adults. Radiology 1989;172:549-554.
15. Gunter JL, Bernstein MA, Borowski BJ, et al. Measurement of MRI scanner performance with the ADNI phantom. Med Phys 2009;36:2193-2205.
16. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
17. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547.
18. McNamee RL, Yee SH, Price JC, et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009;50: 348-355.
19. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
20. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 2005; 46:1959-1972.
21. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32:1207-1218.
22. Campbell I. Chi-squared and Fisher-Irwin tests of two-bytwo tables with small sample recommendations. Stat Med 2007;26:3661-3675.
23. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
24. Bouwman FH, Schoonenboom SN, van der Flier WM, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070-1074.
25. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 2009;73:294-301.
26. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-238.
27. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain β-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-3348.
28. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloidpositive individuals. Cereb Cortex 2008;19:497-510.
29. Pike KE, Savage G, Villemagne VL, et al. β-Amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-2844.
30. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
31. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
32. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010;67:353-364.
33. Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid. Alzheimers Dement 2011;7:133-141.
34. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol 2006;59:512-519.
35. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557-568.
36. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73:1186-1192.
37. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
38. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 2009;73:754-760.
39. Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol 2011;68:351-356.
40. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69: 2197-2204.